In a landmark phase I trial by Liu et al., cord blood–derived anti-CD19 CAR-NK cells administered to patients with lymphoid malignancies demonstrated a favorable safety profile with encouraging efficacy signals and no CRS or neurotoxicity 68. The gene discussed is CD19; the disease is congenital rubella syndrome.